Related by context. Frequent words. (Click for all words.) 66 Paragraph IV certification 65 Paragraph IV Certification 64 ANDA containing 63 Company Nasdaq PRGO 63 Act PDUFA date 63 Generic Version 63 Paragraph IV 62 Application MAA 62 Barr Laboratories Inc. 61 Drug Application 61 Inc. Nasdaq MYL 61 FDA Accepts 61 pediatric exclusivity 61 invalid unenforceable 60 Drug Submission 60 Receives Orphan Drug Designation 60 Citizen Petition 60 Drug Applications ANDAs 60 Synthon 60 Marketing Authorization Application 60 FDA Complete Response 59 Marketing Authorization 59 ZEGERID Capsules 59 Duramed Pharmaceuticals Inc. 59 Complete Response letter 59 Transcept Pharmaceuticals 59 Marketing Authorisation 59 NYSE MYL 59 Penwest Pharmaceuticals 59 NYSE BRL 58 submitted Marketing Authorization 58 Application BLA 58 FastMarkets Ltd 58 Marketing Authorization Application MAA 58 Focetria 58 BioDelivery Sciences 58 supplemental Biologics License Application 58 subsidiary Mylan Pharmaceuticals 58 Par Pharmaceuticals 58 submitted Biologics License 58 Propoxyphene 58 Periostat 58 Complete Response 58 Teva Pharmaceuticals USA 58 See BioWorld Today 58 Inc. Nasdaq SEPR 58 Panzem R 58 approvable letters 58 Teva Pharma 58 Initiates Phase II 58 FDA approvable letter 57 BioGlue R 57 Junovan 57 Argatroban 57 Shelf Registration Statement 57 Abbreviated New 57 Orphan Drug status 57 OsmoPrep 57 Investigational Device Exemption 57 ISTODAX 57 Medicis Pharmaceutical Corporation 57 Intellipharmaceutics 57 Pivotal Phase III 57 through GroupWeb EmailWire.Com 57 Nasdaq BDSI 57 R sorafenib tablets 56 Option Grants 56 Coadministration 56 Nasdaq ADLR 56 gets USFDA nod 56 Connetics Corporation 56 Drug Application ANDA 56 European Medicines Evaluation 56 NASDAQ CYPB 56 Ranexa R 56 PRNewswire FirstCall Barr Pharmaceuticals 56 OPANA ER 56 PROVIGIL 56 www.3dsyndication.com 56 Presents Positive 56 Positive Opinion 56 Swissmedic 56 DISCLOSURE NOTICE 56 Completes Enrollment 56 Patent Infringement Lawsuit 56 Receives Notification 56 IMPAX Laboratories Inc. 56 Extended Release 56 NASDAQ Listing 55 Praecis 55 Antitrust Improvement 55 Andrx Corporation 55 IND Investigational New 55 Protalix BioTherapeutics 55 Fast Track Designation 55 Orphan Drug Status 55 Warning Letter 55 Announces Dismissal 55 Humanitarian Device Exemption 55 Biologics License Application 55 FDA Orphan Drug